Rockwell Medical Technologies, Inc. Announces Closing of $22 Million Registered Direct...

Rockwell Medical Technologies, Inc. Announces Closing of $22 Million Registered
Direct Offering of Shares and Warrants

WIXOM, Mich., Oct. 5, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies,
Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering
innovative products and services targeting end-stage renal disease (ERSD),
chronic kidney disease (CKD), and iron deficiency anemia, announced today that
it has received gross proceeds of approximately $22.0 million, before deducting
placement agents' fees and offering expenses, from the closing of the previously
announced registered direct offering. In the offering, an aggregate of 2,840,000
shares of the Company's common stock and warrants to purchase up to 1,079,200
shares of common stock were sold to institutional investors, led by Deerfield
Management as the lead investor.

The purchase price per unit, consisting of one share and a warrant to purchase
0.38 shares, was $7.75. The warrants will have a five-year term from the date of
issuance, will be exercisable beginning six months after the date of issuance,
and will be exercisable at a price of $9.55 per share. The shares of common
stock and warrants were immediately separable and were issued separately.

Rockwell anticipates that the net proceeds from the offering of approximately
$20.5 million will be used for general corporate purposes, which may include
funding of clinical trials and regulatory activities for soluble ferric
pyrophosphate (SFP), the Company's licensed drug therapy to treat iron
deficiency anemia in dialysis patients, and other research and development
expenses, and general and administrative expenses.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell, stated, "We are
pleased with the mix of new institutional investors and appreciate their strong
vote of confidence in the future of Rockwell as they chose to invest in us at
this time. We expect this funding to be sufficient to finance the remainder of
our FDA clinical development for SFP, our lead drug for treatment of iron
deficiency anemia."

JMP Securities LLC served as lead placement agent and Wedbush Securities Inc.
served as co-placement agents for the offering. Copies of the prospectus
supplement and accompanying base prospectus relating to the public offering may
be obtained from the Securities and Exchange Commission website at
http://www.sec.gov or from Rockwell Medical Technologies, Inc., located at 30142
Wixom Road, Wixom, Michigan 48393 (telephone number: (248) 960-9009), Attn:
Thomas E. Klema, Secretary.

The securities were offered by Rockwell pursuant to a registration statement
previously filed and declared effective by the Securities and Exchange
Commission (File No. 333-160791). This press release does not and shall not
constitute an offer to sell or the solicitation of an offer to buy any of the
securities, nor shall there be any sale of the securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any state or
jurisdiction. Any offer of these securities will be solely by means of a
prospectus included in the registration statement and any prospectus supplement
that may be issued in connection with such offering.

About SFP:

SFP is a novel, investigational, physiological iron maintenance therapy designed
to treat iron deficiency anemia in ESRD patients. SFP is a proprietary,
water-soluble form of iron that travels directly to the bloodstream and
transfers iron at a cellular level, similar to normal, healthy dietary iron
uptake. SFP is designed as a continuous replacement treatment delivering small
doses of iron during every dialysis session in order to offset iron losses
during the dialysis procedure, thereby maintaining hemoglobin in the target
range as per Kidney Disease Quality Outcomes Initiative (KDQOI) recommendations.
Clinical trials to date suggest that SFP, delivered during each dialysis
treatment via dialysate, maintains optimal iron balance and avoids liver
toxicity while decreasing associated drug administration costs. Recent academic
studies have shown that more frequent maintenance doses of iron improve the
therapeutic response and benefits of recombinant erythropoietin treatment.
Rockwell has licensed exclusive worldwide rights to manufacture and sell SFP and
has secured patents for SFP in multiple countries, including the three largest
dialysis markets in the world: the United States, Japan, and the European Union.
Based on current market data, the U.S. dialysis market for IV iron is
approximately $560 million annually while global market potential is
approximately $850 million.

About Rockwell Medical Technologies:

Rockwell is a fully-integrated biopharmaceutical company offering innovative
products and services initially targeting end-stage renal disease (ESRD),
chronic kidney disease (CKD), and iron deficiency anemia. An established
manufacturer and leader in delivering high-quality hemodialysis
concentrates/dialysates to dialysis providers and distributors in the U.S. and
abroad, Rockwell provides products that are used to maintain human life by
removing toxins and replacing critical nutrients in the dialysis patient's
bloodstream. Dialysis is a process that duplicates kidney function for patients
who suffer from ESRD. There are approximately 400,000 ESRD patients in the
United States growing at an annual rate of 4 percent, and approximately 2
million ESRD patients worldwide.

The Company is currently developing unique, proprietary renal drug therapies for
iron treatment. These exclusive renal drug therapies support disease management
initiatives to improve the quality of life and care of dialysis patients and are
designed to deliver safe and effective therapy, while decreasing drug
administration costs and improving patient convenience. Rockwell is developing a
pipeline of drug therapies, including extensions of SFP for indications outside
of hemodialysis. Please visit www.rockwellmed.com for more information.

Certain statements in this press release constitute "forward-looking statements"
within the meaning of the federal securities laws. Words such as "may," "might,"
"will," "should," "believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "projected," "intend" or similar expressions, or
statements regarding intent, belief, or current expectations, are
forward-looking statements. While the Company believes these forward-looking
statements are reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information available to us on
the date of this release. These forward-looking statements are based upon
current estimates and assumptions and are subject to various risks and
uncertainties, including without limitation those set forth in the Rockwell's
SEC filings. Thus, actual results could be materially different. Rockwell
expressly disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as required by
law.

-0-
CONTACT: The Trout Group LLC
Brian Korb, VP
(646) 378-2923

LaVoie Group
Media Contact:
Lisa Rivero, Director, Media Relations
(978) 745-4200 ext. 106